-
Je něco špatně v tomto záznamu ?
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy
T. Yanagisawa, T. Kawada, K. Bekku, E. Laukhtina, P. Rajwa, M. von Deimling, M. Chlosta, F. Quhal, B. Pradere, PI. Karakiewicz, K. Mori, T. Kimura, SF. Shariat, M. Schmidinger
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, metaanalýza, systematický přehled
NLK
Free Medical Journals
od 1999
Medline Complete (EBSCOhost)
od 1999-01-01 do Před 1 rokem
PubMed
38659099
DOI
10.1111/bju.16336
Knihovny.cz E-zdroje
- MeSH
- anilidy * terapeutické užití MeSH
- chinoliny terapeutické užití MeSH
- doba přežití bez progrese choroby MeSH
- fenylmočovinové sloučeniny terapeutické užití MeSH
- humanizované monoklonální protilátky terapeutické užití MeSH
- imunoterapie metody MeSH
- inhibitory kontrolních bodů * terapeutické užití MeSH
- ipilimumab terapeutické užití MeSH
- karcinom z renálních buněk * farmakoterapie mortalita sekundární MeSH
- lidé MeSH
- nádory ledvin * farmakoterapie mortalita patologie MeSH
- nivolumab terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie * terapeutické užití MeSH
- pyridiny terapeutické užití MeSH
- randomizované kontrolované studie jako téma MeSH
- síťová metaanalýza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-based combined therapies. We performed network meta-analysis (NMA) to compare the outcomes, including progression-free survival (PFS) and objective response rates (ORRs), in patients with intermediate- and poor-risk mRCC; we also assessed treatment-related adverse events. RESULTS: Overall, seven RCTs were included in the meta-analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72-1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. CONCLUSIONS: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first-line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.
Clinic of Urology and Urological Oncology Jagiellonian University Krakow Poland
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology La Croix Du Sud Hospital Quint Fonsegrives France
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019191
- 003
- CZ-PrNML
- 005
- 20241024111647.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bju.16336 $2 doi
- 035 __
- $a (PubMed)38659099
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000274100712
- 245 10
- $a First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy / $c T. Yanagisawa, T. Kawada, K. Bekku, E. Laukhtina, P. Rajwa, M. von Deimling, M. Chlosta, F. Quhal, B. Pradere, PI. Karakiewicz, K. Mori, T. Kimura, SF. Shariat, M. Schmidinger
- 520 9_
- $a OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-based combined therapies. We performed network meta-analysis (NMA) to compare the outcomes, including progression-free survival (PFS) and objective response rates (ORRs), in patients with intermediate- and poor-risk mRCC; we also assessed treatment-related adverse events. RESULTS: Overall, seven RCTs were included in the meta-analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72-1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. CONCLUSIONS: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first-line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a anilidy $x terapeutické užití $7 D000813
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 12
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 12
- $a karcinom z renálních buněk $x farmakoterapie $x mortalita $x sekundární $7 D002292
- 650 12
- $a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a ipilimumab $x terapeutické užití $7 D000074324
- 650 12
- $a nádory ledvin $x farmakoterapie $x mortalita $x patologie $7 D007680
- 650 _2
- $a síťová metaanalýza $7 D000071076
- 650 _2
- $a nivolumab $x terapeutické užití $7 D000077594
- 650 _2
- $a fenylmočovinové sloučeniny $x terapeutické užití $7 D010671
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a pyridiny $x terapeutické užití $7 D011725
- 650 _2
- $a chinoliny $x terapeutické užití $7 D011804
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000283699712
- 700 1_
- $a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000300021592
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000289530272
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland $1 https://orcid.org/0000000340736584
- 700 1_
- $a von Deimling, Markus $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Chlosta, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Clinic of Urology and Urological Oncology, Jagiellonian University, Krakow, Poland
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Québec, Canada
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000261476569
- 700 1_
- $a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Schmidinger, Manuela $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 773 0_
- $w MED00011371 $t BJU international $x 1464-410X $g Roč. 134, č. 3 (2024), s. 323-336
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38659099 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111640 $b ABA008
- 999 __
- $a ok $b bmc $g 2201809 $s 1231164
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 134 $c 3 $d 323-336 $e 20240424 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
- LZP __
- $a Pubmed-20241015